NCT06310616View on ClinicalTrials.gov

A Study to Investigate the Potential Drug-Drug Interaction Between VH4524184 and Oral Contraceptive (Loestrin) in Healthy Adult Female Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

26

Participants

Timeline

Start Date

March 6, 2024

Primary Completion Date

August 15, 2024

Study Completion Date

August 15, 2024

Conditions

HIV Infections

Interventions

DRUG

VH4524184

VH4524184 will be administered.

DRUG

Loestrin

Loestrin will be administered.

Trial Locations (1)

78209

GSK Investigational Site, San Antonio

Sponsors

Lead Sponsor

ViiV Healthcare

All Listed Sponsors

lead

ViiV Healthcare

INDUSTRY

NCT06310616 - A Study to Investigate the Potential Drug-Drug Interaction Between VH4524184 and Oral Contraceptive (Loestrin) in Healthy Adult Female Participants | Biotech Hunter | Biotech Hunter